For decades, the scientific and medical communities have largely understood prescription stimulant medications, such as Ritalin and Adderall, to primarily enhance attention directly in individuals with attention deficit hyperactivity disorder (ADHD). These drugs, widely used to manage ADHD symptoms in an estimated 3.5 million children aged 3 to 17 in the United States alone—a number that has steadily climbed with increased diagnoses of the neurodevelopmental disorder—have been thought to directly modulate brain regions responsible for focus and cognitive control. However, groundbreaking new research from Washington University School of Medicine in St. Louis is poised to significantly alter this long-held paradigm, suggesting that these medications operate through a different, perhaps more nuanced, mechanism: by influencing brain systems tied to reward and wakefulness rather than directly sharpening traditional attention networks.
Published on December 24 in the prestigious journal Cell, the study, spearheaded by Benjamin Kay, MD, PhD, an assistant professor of neurology, and Nico U. Dosenbach, MD, PhD, the David M. & Tracy S. Holtzman Professor of Neurology, presents compelling evidence that stimulants may improve performance in individuals with ADHD by making them feel more alert and inherently more interested in the tasks at hand. This re-evaluation proposes that instead of directly enhancing an individual’s capacity to focus, the drugs appear to elevate engagement with activities, essentially making typically challenging or unrewarding tasks more palatable and compelling. Intriguingly, the researchers also observed brain activity patterns remarkably similar to those seen after a restorative night’s sleep, effectively counteracting the typical neural signatures associated with sleep deprivation.
The Evolving Understanding of ADHD and Its Treatment
ADHD is a complex neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. Its recognition as a distinct condition has evolved over the past century, with formal diagnostic criteria becoming standardized in the latter half of the 20th century. Historically, the understanding of ADHD’s underlying neurobiology has centered on dysregulation of neurotransmitters, particularly dopamine and norepinephrine, in the prefrontal cortex—a brain region critical for executive functions like attention, planning, and impulse control. Stimulant medications, which increase the availability of these neurotransmitters in the synaptic cleft, were thus believed to bolster the function of these executive control circuits, thereby directly improving attention.
The prevalence of ADHD diagnoses has seen a notable increase globally, mirroring the trend in the U.S. This rise can be attributed to several factors, including improved diagnostic tools, greater awareness among parents and educators, and a broader understanding of how ADHD manifests across different age groups and genders. With this increased diagnosis comes a greater reliance on pharmacological interventions, particularly stimulants, which have demonstrated efficacy in managing symptoms for many individuals. Consequently, a deeper and more accurate understanding of their precise mechanism of action is not merely an academic exercise but holds profound implications for clinical practice, patient outcomes, and future therapeutic development.
Unveiling the Brain’s Hidden Mechanisms: The WashU Study
Dr. Kay, who treats patients at St. Louis Children’s Hospital, reflected on the long-standing medical doctrine regarding stimulants. "I prescribe a lot of stimulants as a child neurologist, and I’ve always been taught that they facilitate attention systems to give people more voluntary control over what they pay attention to," he stated. However, the new findings from his team’s research directly challenge this conventional wisdom. "But we’ve shown that’s not the case. Rather, the improvement we observe in attention is a secondary effect of a child being more alert and finding a task more rewarding, which naturally helps them pay more attention to it." This perspective shift suggests that the primary effect isn’t a direct enhancement of attentional control but an indirect one, mediated by increased alertness and perceived reward.
Dr. Dosenbach further elaborated on this "pre-rewarding" effect. He explained that stimulants essentially prime the brain to find tasks that would typically be uninteresting or arduous—such as rote schoolwork—more engaging. "Essentially, we found that stimulants pre-reward our brains and allow us to keep working at things that wouldn’t normally hold our interest — like our least favorite class in school, for example," Dosenbach noted. This heightened sense of reward helps children persist through challenging and repetitive activities, which are often major hurdles for those with ADHD.
The study’s findings also offer a compelling explanation for how stimulants address hyperactivity, a symptom that previously posed a paradox given the traditional understanding of stimulant action. "These results also provide a potential explanation for how stimulants treat hyperactivity, which previously seemed paradoxical," Dosenbach added. He posited that the restless, fidgety behaviors characteristic of hyperactivity often stem from a child’s inability to focus on unrewarding tasks. By making these tasks more rewarding, stimulants allow children to "sit still better because they’re not getting up to find something better to do." This recontextualization of stimulant action provides a more holistic understanding of their therapeutic breadth.
Methodology: A Deep Dive into Brain Imaging
To meticulously investigate how stimulants exert their effects on the brain, the research team employed sophisticated brain imaging techniques. They analyzed resting state functional MRI (fMRI) data gleaned from a substantial cohort of 5,795 children, aged 8 to 11, who were participants in the Adolescent Brain Cognitive Development (ABCD) Study. Resting state fMRI is a powerful neuroimaging tool that measures spontaneous fluctuations in brain activity when an individual is not engaged in a specific task, providing insights into the brain’s intrinsic functional connectivity.
The ABCD Study itself is an monumental undertaking: a long-term, multisite project tracking the brain development of over 11,000 children across the United States, including a prominent site at Washington University School of Medicine. This unprecedented scale and longitudinal design make the ABCD Study an invaluable resource for understanding childhood development, mental health, and the impact of various factors, including medication, on the developing brain. By leveraging this rich dataset, the WashU team was able to compare brain connectivity patterns in children who had taken prescription stimulants on the day of their fMRI scan with those who had not.
The analysis yielded striking and unexpected patterns. Children who had taken stimulants exhibited significantly stronger activity in brain regions specifically associated with arousal and wakefulness. Concurrently, increased activity was observed in areas involved in predicting how rewarding an activity might be. Crucially, and contrary to prevailing theories, the fMRI scans did not reveal any notable increases in activity within the brain regions classically identified as being central to direct attentional control.
To further validate these findings and ensure their robustness, the researchers conducted a smaller, targeted study involving five healthy adults who did not have ADHD and typically did not take stimulant medications. Each participant underwent resting state fMRI scans both before and after receiving a single dose of a stimulant. This within-subject design allowed the team to precisely track individual changes in brain connectivity induced by the medication. The adult experiment unequivocally confirmed the observations from the larger pediatric cohort: the stimulant medications consistently activated reward and arousal networks, rather than the traditionally posited attention networks.
The Critical Role of Sleep in ADHD Management
One of the most profound implications of the study emerged from its investigation into the interplay between stimulant use, sleep quality, and cognitive performance. Within the ABCD study population, children diagnosed with ADHD who were taking stimulant medications consistently demonstrated superior academic performance, as reported by their parents, and achieved better scores on cognitive tests compared to their counterparts with ADHD who were not on stimulants. This beneficial effect was particularly pronounced in children presenting with more severe ADHD symptoms, reinforcing the clinical efficacy of these medications.
However, the benefits were not universally observed, leading to a crucial discovery. The study revealed a significant interaction with sleep patterns. Among participants who reported sleeping less than the recommended nine or more hours per night—a common issue in modern society, with estimates suggesting that a substantial percentage of children and adolescents do not get adequate sleep—those who took stimulants earned better grades than similarly sleep-deprived children who did not take the medication. This suggests that stimulants might be effectively "masking" the cognitive deficits associated with insufficient sleep. In stark contrast, stimulants were not linked to improved cognitive performance in neurotypical children who were consistently getting enough sleep, indicating that the benefits are not a general cognitive enhancement but rather specific to certain physiological or pathological states. While the reasons for neurotypical children taking stimulants were not detailed, their inclusion provided a valuable control group. Overall, the link between stimulants and improved cognitive performance appeared to manifest predominantly in children with ADHD or in those experiencing chronic sleep deprivation.
Dr. Dosenbach articulated this remarkable finding: "We saw that if a participant didn’t sleep enough, but they took a stimulant, the brain signature of insufficient sleep was erased, as were the associated behavioral and cognitive decrements." This observation is pivotal, as it points to a dual mechanism of benefit—addressing ADHD symptoms directly while also potentially compensating for the profound negative effects of sleep loss.
Navigating the Ethical Landscape and Clinical Implications
While the ability of stimulants to mitigate the effects of poor sleep might seem advantageous in the short term, the researchers issued a significant caution regarding the potential long-term consequences of masking sleep deprivation. "Not getting enough sleep is always bad for you, and it’s especially bad for kids," Dr. Kay emphasized. He highlighted that overtired children frequently exhibit symptoms that closely mimic ADHD, including difficulties with attention, concentration in academic settings, and a decline in grades. This overlap presents a serious risk of misdiagnosis, where chronic sleep deprivation, rather than ADHD, is the primary underlying issue.
In such scenarios, stimulant medications, by mimicking some of the beneficial effects of adequate sleep, might appear to alleviate symptoms, inadvertently delaying the identification and treatment of the actual problem. This could leave children exposed to the cumulative and potentially severe long-term harms of chronic sleep loss, which can impact growth, development, immune function, mood regulation, and overall cognitive health. Dr. Kay, therefore, strongly urged clinicians to integrate comprehensive sleep evaluations into their diagnostic process for ADHD and to actively explore and recommend strategies to improve sleep hygiene and quality. This call for a more holistic assessment underscores a critical shift in clinical best practices.
Broader Impact and Future Directions
The findings from Washington University School of Medicine carry profound implications that extend beyond immediate clinical practice. They are poised to influence diagnostic criteria and treatment guidelines for ADHD, potentially leading to a more nuanced approach that prioritizes sleep assessment and intervention alongside traditional pharmacological strategies. This research could also steer future pharmaceutical development, shifting the focus towards designing drugs that specifically target reward and wakefulness pathways, or exploring novel non-stimulant alternatives that address these mechanisms.
From a public health perspective, the study amplifies the critical importance of sleep hygiene, particularly for children and adolescents. It serves as a potent reminder that while medication can be a valuable tool, it should not be seen as a panacea or a substitute for fundamental health practices. Educational campaigns focusing on the necessity of adequate sleep could gain new urgency in light of these findings.
Despite the significant advancements, Dr. Dosenbach and Dr. Kay acknowledge that their findings open new avenues for research, highlighting several unanswered questions. They suggest that stimulants might play a restorative role by activating the brain’s waste-clearing system during wakefulness, a hypothesis that warrants further investigation. Conversely, the medications could potentially cause lasting harm if they are chronically used to compensate for ongoing sleep deficits, raising concerns about neurodevelopmental trajectories. The long-term effects of stimulant use on brain development and function, particularly when sleep patterns are compromised, remain areas for urgent inquiry. Furthermore, the role of other factors such as diet, exercise, and behavioral interventions in conjunction with these newly understood mechanisms of action requires deeper exploration.
This pivotal research not only redefines our understanding of how ADHD stimulant medications work but also initiates a crucial dialogue within the medical community and among the public about the interconnectedness of brain function, medication, and fundamental physiological needs like sleep. It paves the way for a more integrated, patient-centered approach to ADHD management, emphasizing careful diagnosis and comprehensive care that considers the full spectrum of a child’s health and well-being.
Citation: Kay BP, Wheelock MD, Siegel JS, Raut R, Chauvin RJ, Metoki A, Rajesh A, Eck A, Pollaro J, Wang A, Suljic V, Adeyemo B, Baden NJ, Scheidter KM, Monk JS, Whiting FI, Ramirez-Perez N, Krimmel SR, Shinohara RT, Tervo-Clemmens B, Hermosillo RJM, Nelson SM, Hendrickson TJ, Madison T, Moore LA, Miranda-Domínguez O, Randolph A, Feczko E, Roland JL, Nicol GE, Laumann TO, Marek S, Gordon EM, Raichle ME, Barch DM, Fair DA, and Dosenbach NUF. Stimulant medications affect arousal and reward, not attention networks. Cell. Dec. 24, 2025. DOI: 10.1016/j.cell.2025.11.039
This work was supported by NIH grants NS140256 (EMG, NUFD), EB029343 (MW), MH121518 (SM), MH129493 (DMB), NS123345 (BPK), NS098482 (BPK), DA041148 (DAF), DA04112 (DAF), MH115357 (DAF), MH096773 (DAF and NUFD), MH122066 (EMG, DAF, and NUFD), MH121276 (EMG, DAF, and NUFD), MH124567 (EMG, DAF, and NUFD), and NS129521 (EMG, DAF, and NUFD); by the National Spasmodic Dysphonia Association (EMG); by Mallinckrodt Institute of Radiology pilot funding (EMG); by the Andrew Mellon Predoctoral Fellowship from the Dietrich School of Arts & Sciences, University of Pittsburgh (BTC); and by the Extreme Science and Engineering Discovery Environment (XSEDE) Bridges at the Pittsburgh Supercomputing Center through allocation TG-IBN200009 (BTC).
Computations were performed using the facilities of the Washington University Research Computing and Informatics Facility (RCIF). The RCIF has received funding from NIH S10 program grants: 1S10OD025200-01A1 and 1S10OD030477-01.
This article reflects the view of the authors and may not reflect the opinions or views of the NIH or ABCD consortium investigators.
